Blue Jet Healthcare reports strong half-year growth, strategic initiatives

Blue Jet Healthcare Limited reported a 40% increase in revenue from operations for H1 FY26, reaching INR 5,202 million. EBITDA grew by 55% to INR 1,759 million (34% Margin) and PAT was up 49% to INR 1,433 million (28% Margin) compared to H1 FY25. For Q2 FY26, revenue from operations was INR 1,655 million, EBITDA was INR 549 million (33% Margin), and PAT was INR 521 million (32% Margin). The company attributed a Q2 revenue decrease to de-stocking in the Pharma Intermediates (PI) segment but highlighted strong other income of INR 243 million, boosted by foreign exchange gains and treasury income.

Key business updates include the launch of an iodinated-based advance contrast media intermediate, robust growth in the MRI segment, and new RFPs for high-conviction Phase 3 and commercialized products. The company also announced the acquisition of 102 acres of land near Vizag for INR 420 million and capex investment of over INR 820 million for backward integration at its Mahad project. Cash and Cash Equivalents plus Treasury Investments stood at INR 3,413 million as of September 30, 2025.